From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.
about
Immunotoxicity of monoclonal antibodiesImmunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsCells and cell lysates: a direct approach for engineering antibodies against membrane proteins using yeast surface displayGeneration of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" miceA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsNeutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery.Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab.Phage display and molecular imaging: expanding fields of vision in living subjects.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regionsEngineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomasDeveloping the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Selection of single domain antibodies from immune libraries displayed on the surface of E. coli cells with two β-domains of opposite topologies.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidatesYeast Display-Based Antibody Affinity Maturation Using Detergent-Solubilized Cell Lysates.Ligand-targeted theranostic nanomedicines against cancerPredicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modellingNanocell targeting using engineered bispecific antibodies.Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancerGene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft modelsMonoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Novel human antibody therapeutics: the age of the Umabs.Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.Potential of ErbB4 antibodies for cancer therapy.Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceApplicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.PK-PD modeling of protein drugs: implications in assay development.Using monoclonal antibodies to stimulate antitumor cellular immunity.Monoclonal antibodies based on hybridoma technology.Discovery of functional antibodies targeting ion channels.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform.Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer
P2860
Q24653374-65531A60-8113-48AC-882B-D73449135F0FQ26738810-D0A52839-0A49-43BF-9A3F-17BD3B4BB8D7Q26849777-1403D0F7-0599-4F50-B5A8-871E71BDCB41Q28749033-581E8010-AC95-4376-8690-A4F3D5F1101EQ28749085-B1AFFEA4-98AA-4780-8878-C0BCEACCA84CQ33412190-193C2971-94B0-4B54-A511-0E9C14A9CE6CQ33646271-50904247-B820-42F6-BF3D-1B754A328035Q33761180-193EA483-13CC-488E-BB2C-256F14BEB3E1Q33849788-FFE95474-23BC-45B2-913A-0AB7A3ADCE54Q34110768-C55B451D-6EF3-48ED-951F-1742ABB23D35Q34193791-31FD9837-6238-44A7-A3BC-BD70F26A735BQ34672043-6978C91D-9AFF-42F5-B524-83A52F3B4EE7Q35005394-8590559A-197D-4AD7-951A-236527775714Q35569418-447A1752-D6ED-4D19-921B-C0C169B067A2Q35578028-50F78892-DABC-403D-AC64-56990796A9B6Q35659193-1A6F964C-0C41-4A06-8F06-958734A10350Q35895637-C37BBA2B-681D-466F-8657-6A5EB3F41B79Q35905876-C6DE50D4-5E05-40DF-A46B-65CED749AA31Q36211456-5D5DB357-D1D1-420B-81C5-F48C78A615E2Q36213066-55DEB62F-F74D-4A75-9E94-8A6EA67D19CBQ36402296-954EC391-E6EE-4641-BF09-5A70B2572D6DQ36629392-E887F5E2-BA91-4440-9D8C-95A8B7531247Q36922576-8150C26C-E154-443F-A4BC-B86CAF857693Q37138420-197A613A-B9A7-42F7-90EF-612B06635063Q37243228-2BF2A9DB-23D3-4E53-8B6B-8A30C371FC48Q37593624-10186C8B-B702-4ECA-A0B4-7979592DA596Q37597698-C37B68AA-34C4-405B-BEEA-9079BE502AB8Q37615896-69EEB125-1089-4262-BCDC-A560678035A4Q37658764-2DB712F2-B718-415A-8D61-67FFC6FEDCD7Q37702015-222CF252-560E-44B2-B319-9902728B6252Q37702078-F15E7449-EEB9-4A69-8B41-0B4FBD092D01Q37719187-8FF62A85-68E1-47FF-9137-D8303A62EB3CQ37854638-A1B783F8-C1EA-4AC3-A40D-9B8782B20FDBQ37909430-F07D363E-2451-4A36-9D0E-36D7C98D2F72Q38162972-2DBAB295-6BAA-4369-9F5B-CA5ECCB62E7CQ38282832-CBC62F21-03FB-49F2-AA04-8FAC68A2EF9DQ38289992-DAF117EE-9F0A-48E9-B5F1-51F1C74B0DF8Q38728582-7AB87677-7ABC-45FE-BF93-0584C60CC533Q38798188-ED9FE37E-EFAB-4C66-8C32-EFA02C1CBACEQ39939644-5638BD22-EC30-4493-97C9-2E25EB8B3CFB
P2860
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
From XenoMouse technology to p ...... product from transgenic mice.
@en
type
label
From XenoMouse technology to p ...... product from transgenic mice.
@en
prefLabel
From XenoMouse technology to p ...... product from transgenic mice.
@en
P2093
P356
P1433
P1476
From XenoMouse technology to p ...... product from transgenic mice.
@en
P2093
Aya Jakobovits
Gisela Schwab
Lorin Roskos
Rafael G Amado
Xiaodong Yang
P2888
P304
P356
10.1038/NBT1337
P577
2007-10-01T00:00:00Z